I-Tech AB (ITECH.ST)
SEK 54.5
(-1.8%)
SEK 54.5
(-1.8%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 120.86 Million SEK | 44.52% |
| 2022 | 83.63 Million SEK | 58.09% |
| 2021 | 52.9 Million SEK | 0.16% |
| 2020 | 52.81 Million SEK | 15.9% |
| 2019 | 45.57 Million SEK | 57.44% |
| 2018 | 28.94 Million SEK | 62.18% |
| 2017 | 17.84 Million SEK | 4.83% |
| 2016 | 17.02 Million SEK | 232.3% |
| 2015 | 5.12 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 42.61 Million SEK | 11.34% |
| 2024 Q3 | 40.76 Million SEK | -4.33% |
| 2024 Q1 | 38.27 Million SEK | 51.43% |
| 2023 Q1 | 30.75 Million SEK | 1.77% |
| 2023 FY | 120.86 Million SEK | 44.52% |
| 2023 Q4 | 25.27 Million SEK | -21.45% |
| 2023 Q3 | 32.17 Million SEK | -1.47% |
| 2023 Q2 | 32.65 Million SEK | 6.17% |
| 2022 Q1 | 14.47 Million SEK | 22.56% |
| 2022 FY | 83.63 Million SEK | 58.09% |
| 2022 Q4 | 30.22 Million SEK | 42.04% |
| 2022 Q3 | 21.27 Million SEK | 20.52% |
| 2022 Q2 | 17.65 Million SEK | 21.94% |
| 2021 Q1 | 14.45 Million SEK | 29.23% |
| 2021 Q3 | 13.81 Million SEK | 7.74% |
| 2021 Q4 | 11.81 Million SEK | -14.47% |
| 2021 FY | 52.9 Million SEK | 0.16% |
| 2021 Q2 | 12.81 Million SEK | -11.34% |
| 2020 Q4 | 11.18 Million SEK | -6.42% |
| 2020 Q3 | 11.95 Million SEK | -25.97% |
| 2020 Q1 | 13.52 Million SEK | -7.26% |
| 2020 FY | 52.81 Million SEK | 15.9% |
| 2020 Q2 | 16.15 Million SEK | 19.41% |
| 2019 Q2 | 12.58 Million SEK | 103.92% |
| 2019 FY | 45.57 Million SEK | 57.44% |
| 2019 Q4 | 14.58 Million SEK | 19.17% |
| 2019 Q3 | 12.23 Million SEK | -2.73% |
| 2019 Q1 | 6.17 Million SEK | -43.24% |
| 2018 Q2 | 9.27 Million SEK | 143.12% |
| 2018 FY | 28.94 Million SEK | 62.18% |
| 2018 Q3 | 4.99 Million SEK | -46.14% |
| 2018 Q1 | 3.81 Million SEK | -46.72% |
| 2018 Q4 | 10.87 Million SEK | 117.7% |
| 2017 Q3 | 5.56 Million SEK | 11.69% |
| 2017 Q1 | 138 Thousand SEK | 0.0% |
| 2017 Q2 | 4.98 Million SEK | 3513.04% |
| 2017 Q4 | 7.15 Million SEK | 28.5% |
| 2017 FY | 17.84 Million SEK | 4.83% |
| 2016 FY | 17.02 Million SEK | 232.3% |
| 2015 FY | 5.12 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | -107.997% |
| Ziccum AB (publ) | 3.74 Million SEK | -3125.54% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 80.38% |
| Sprint Bioscience AB (publ) | 50.48 Million SEK | -139.4% |
| Mendus AB (publ) | 28.48 Million SEK | -324.267% |
| Genovis AB (publ.) | 158.23 Million SEK | 23.618% |
| Intervacc AB (publ) | 8.01 Million SEK | -1407.935% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -2663.169% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 29.089% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -175.335% |
| Aptahem AB (publ) | 2.63 Million SEK | -4494.343% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -11577.391% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -156862.338% |
| Fluicell AB (publ) | 3.33 Million SEK | -3520.761% |
| Saniona AB (publ) | 16.84 Million SEK | -617.702% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -636.643% |
| Biovica International AB (publ) | 7.29 Million SEK | -1557.901% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -9946.633% |
| AcouSort AB (publ) | 10.55 Million SEK | -1045.493% |
| Xintela AB (publ) | 78 Thousand SEK | -154850.0% |
| Abliva AB (publ) | 137 Thousand SEK | -88119.708% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | -109.828% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -5901.043% |
| OncoZenge AB (publ) | 3000.00 SEK | -4028600.0% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -77874.839% |
| CombiGene AB (publ) | 5.54 Million SEK | -2079.986% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 89.986% |
| Camurus AB (publ) | 1.71 Billion SEK | 92.96% |
| Corline Biomedical AB | 25.03 Million SEK | -382.865% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -2028.584% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -16662.968% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 9.868% |
| Cyxone AB (publ) | 5.14 Million SEK | -2247.727% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -1614.34% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -1033.281% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -976.227% |
| Nanologica AB (publ) | 1.44 Million SEK | -8275.676% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -227939.623% |
| BioInvent International AB (publ) | 71.46 Million SEK | -69.129% |
| Alzinova AB (publ) | 270 Thousand SEK | -44663.333% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -243.16% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -8161.063% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -4182.814% |
| Simris Alg AB (publ) | 4.35 Million SEK | -2675.861% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -92870.0% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 49.373% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -525382.609% |